EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Role of Luteolin as Potential New Therapeutic Option for Patients with Glioblastoma through Regulation of Sphingolipid Rheostat

Stefania Elena Navone iD, Laura Guarnaccia, Massimiliano D Rizzaro, Laura Begani, Emanuela Barilla, Giovanni Alotta, Emanuele Garzia iD, Manuela Caroli, Antonella Ampollini, Aniello Violetti, Noreen Gervasi iD, Rolando Campanella und 3 weitere

International Journal of Molecular Sciences · 21.12.2023 · 25 (1) · 130

DOI: 10.3390/ijms25010130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.12.2023. Verfasst von Stefania Elena Navone und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, …. Hauptthemen laut MEDLINE: Sphingolipids, Glioblastoma, Lysophospholipids. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Fondazione Cariplo, Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most aggressive brain tumor, still considered incurable. In this study, conducted on primary GBM stem cells (GSCs), specifically selected as the most therapy-resistant, we examined the efficacy of luteolin, a natural flavonoid, as an anti-tumoral compound. Luteolin is known to impact the sphingolipid rheostat, a pathway regulated by the proliferative sphingosine-1-phosphate (S1P) and the proapoptotic ceramide (Cer), and implicated in numerous oncopromoter biological processes. Here, we report that luteolin is able to inhibit the expression of SphK1/2, the two kinases implicated in S1P formation, and to increase the expression of both SGPL1, the lyase responsible for S1P degradation, and CERS1, the ceramide synthase 1, thus shifting the balance toward the production of ceramide. In addition, luteolin proved to decrease the expression of protumoral signaling as MAPK, RAS/MEK/ERK and PI3K/AKT/mTOR and cyclins involved in cell cycle progression. In parallel, luteolin succeeded in upregulation of proapoptotic mediators as caspases and Bcl-2 family and cell cycle controllers as p53 and p27. Furthermore, luteolin determined the shutdown of autophagy contributing to cell survival. Overall, our data support the use of luteolin as add-on therapy, having demonstrated a good ability in impairing GSC viability and survival and increasing cell sensitivity to TMZ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SphingolipidsGlioblastomaLysophospholipidsHumansLuteolinPhosphatidylinositol 3-KinasesCeramidesSphingosine

Stichwörter der Autor:innen

ceramideglioblastoma stem cellsglioma stem cellsluteolinsphingolipid rheostatsphingosine-1-phosphatetemozolomide

Substanzen

SphingolipidsLuteolinPhosphatidylinositol 3-KinasesCeramidessphingosine 1-phosphateLysophospholipidsSphingosine

Autor:innen und Institutionen

  • Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
  • Andremacon Biotech Srl, Viale Ortles, 22/4, 20141 Milan, Italy.
  • Reproductive Medicine Unit, Department of Mother and Child, San Paolo Hospital Medical School, ASST Santi Paolo e Carlo, 20142 Milan, Italy.
  • Aerospace Medicine Institute "A. Mosso", Italian Air Force, 20138 Milan, Italy.
  • Space Attache', Embassy of Italy in Washington DC, Washington, DC 20008, USA.
  • Alcamena Stem Cell Therapeutics, 1450 South Rolling Road, Suite 4.069, Halethorpe, MD 21227, USA.

ORCID-Profile: Stefania Elena Navone, Emanuele Garzia, Noreen Gervasi

Förderung

  • Ministero della Salute
  • Fondazione Cariplo
  • Italian Ministry of Health

Zitieren

APA

Navone, S. E., Guarnaccia, L., Rizzaro, M. D., Begani, L., Barilla, E., Alotta, G., Garzia, E., Caroli, M., Ampollini, A., Violetti, A., Gervasi, N., Campanella, R., Riboni, L., Locatelli, M., & Marfia, G. (2023). Role of Luteolin as Potential New Therapeutic Option for Patients with Glioblastoma through Regulation of Sphingolipid Rheostat. International Journal of Molecular Sciences, 25(1), 130. https://doi.org/10.3390/ijms25010130

Vancouver

Navone SE, Guarnaccia L, Rizzaro MD, Begani L, Barilla E, Alotta G, et al. Role of Luteolin as Potential New Therapeutic Option for Patients with Glioblastoma through Regulation of Sphingolipid Rheostat. International Journal of Molecular Sciences. 2023;25(1):130. doi:10.3390/ijms25010130

BibTeX
@article{Navone2023,
  author = {Navone, Stefania Elena and Guarnaccia, Laura and Rizzaro, Massimiliano D and Begani, Laura and Barilla, Emanuela and Alotta, Giovanni and Garzia, Emanuele and Caroli, Manuela and Ampollini, Antonella and Violetti, Aniello and Gervasi, Noreen and Campanella, Rolando and Riboni, Laura and Locatelli, Marco and Marfia, Giovanni},
  title = {Role of Luteolin as Potential New Therapeutic Option for Patients with Glioblastoma through Regulation of Sphingolipid Rheostat},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {25},
  number = {1},
  pages = {130},
  doi = {10.3390/ijms25010130}
}
Kostenlos starten →